Ed Arce is a Managing Director of Equity Research at H.C. Wainwright with expertise in both the biopharmaceutical and the specialty pharmaceutical sectors. In particular, Mr. Arce’s research covers investment opportunities among hepatology, renal, infectious disease, gastrointestinal, endocrine, metabolic and select rare disease companies Mr. Arce has been involved in institutionally-focused healthcare research since 2005. Prior to joining H.C. Wainwright, Mr. Arce was a Senior Research Analyst at ROTH Capital Partners. Mr. Arce’s previous sell-side experience includes working for MLV & Co, Wedbush Securities, UBS Securities and First Albany Capital.
Article: Summit Therapeutics (SMMT) Receives a Buy from H.C. Wainwright
Article - MediaSummit Therapeutics (SMMT) Receives a Buy from H.C. Wainwright
Austin Angelo
AnalystRatings, 1 May 2020
H.C. Wainwright analyst Ed Arce maintained a Buy rating on Summit Therapeutics (SMMT – Research Report) today and set a price target of $4.00. The company’s shares closed last Thursday at $3.75.
According to TipRanks.com, Arce is a 5-star analyst with an average return of 14.2% and a 41.9% success rate. Arce covers the Healthcare sector, focusing on stocks such as Entasis Therapeutics Holdings, Madrigal Pharmaceuticals, and Collegium Pharmaceutical.
Comment: This company is at risk of collusion between a placement agent and naked short sellers.
